EUVIMEDEUVIMED entdecken
Crossref

L26/P-770 Age-dependent effectiveness of short-term growth hormone regimen on oocyte yield and FSH dosing in POSEIDON group 4 patients: A real-world evidence study

N.T. Ho, T.M.T. Luong, T.M. Ho, L.N. Vuong, K. Shu-Huei, C.R. Tzeng

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N.T. Ho und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does short-term growth hormone (GH) supplementation differentially affect IVF outcomes across age subgroups in POSEIDON group 4 poor responders? Summary answer In women aged ≥40, GH use improves oocyte yield and embryo numbers and reduces required FSH dose and cycle cancellation rates. What is known already GH has been proposed to enhance ovarian response through GH/IGF-1 pathways, particularly in women with diminished ovarian reserve. Evidence regarding its clinical effectiveness remains inconsistent, partly due to heterogeneous study populations and inadequate stratification by age. The POSEIDON group 4 category represents the most severe subset of poor responders, where age-related decline and possible GH/IGF-1 insufficiency may influence treatment outcomes. Whether GH provides age-specific benefits in this difficult-to-treat population remains unclear. Study design, size, duration This retrospective cohort study included 1,847 IVF cycles from women fulfilling POSEIDON group 4 criteria. Outcomes were compared between GH-supplemented and non-supplemented cycles over a multi-year period. Subgroup analyses stratified by age and multivariable linear regression were performed to assess the independent effect of GH on oocyte yield. Participants/materials, setting, methods Women received a short-term GH regimen of 8 IU/day for 3 days, starting on the second day of ovarian stimulation with exogenous FSH. IVF outcomes—including total oocyte yield, number of MII oocytes, cleavage rates, cycle cancellation, and total FSH dose requirements—were compared between groups. Subgroup analyses were performed according to age categories (35–39, 40–42, and ≥43 years). Multivariable regression was used to control for confounders and assess independent associations between GH use and oocyte yield. Main results and the role of chance GH significantly improved outcomes in women ≥40 (n = 1440). Compared with controls, GH increased oocyte yield (3.97±2.89 vs 2.89±2.58), MII oocytes (2.86±2.35 vs 2.22±2.18), cleavages (2.50±2.20 vs 1.91±2.13), and reduced the risk of cycle cancellation due to no oocytes (7.5% vs 13.4%). GH supplementation also significantly reduced the total FSH dose required (1496±876 vs 1740±1125) (all p < 0.05). Benefits were more pronounced in women ≥43 than those aged 40–42, with greater mean differences in oocyte (1.38 vs 1.00) and MII numbers (0.85 vs 0.57) (p < 0.05). Multiple linear regression analysis confirmed GH as an independent predictor of oocyte yield (B-value=0.60, 95%CI 0.37–0.80, β = 0.11, p < 0.05). In contrast, women aged 35–39 (n = 407) showed no improvement in total number of oocytes, MII oocytes, cleavages, or cancellation rate (all p > 0.05). The rates of good-quality cleavage were comparable across all groups, irrespective of GH use. Pregnancy outcomes following the first embryo transfer, including implantation and clinical pregnancy rates, did not differ significantly between groups (p > 0.05). Limitations, reasons for caution Retrospective design may limit causal inference. Findings require confirmation in randomized trials. Wider implications of the findings GH may be selectively beneficial for older POSEIDON group 4 patients, likely reflecting age-related GH/IGF-1 insufficiency. Its effects appear limited to improving oocyte and embryo quantity rather than quality. Furthermore, GH supplementation appears to confer greater benefits in older patients. Trial registration number No

Zitieren

APA

Ho, N., Luong, T., Ho, T., Vuong, L., Shu-Huei, K., & Tzeng, C. (2026). L26/P-770 Age-dependent effectiveness of short-term growth hormone regimen on oocyte yield and FSH dosing in POSEIDON group 4 patients: A real-world evidence study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1097

Vancouver

Ho N, Luong T, Ho T, Vuong L, Shu-Huei K, Tzeng C. L26/P-770 Age-dependent effectiveness of short-term growth hormone regimen on oocyte yield and FSH dosing in POSEIDON group 4 patients: A real-world evidence study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1097

BibTeX
@article{Ho2026,
  author = {Ho, N.T. and Luong, T.M.T. and Ho, T.M. and Vuong, L.N. and Shu-Huei, K. and Tzeng, C.R.},
  title = {L26/P-770 Age-dependent effectiveness of short-term growth hormone regimen on oocyte yield and FSH dosing in POSEIDON group 4 patients: A real-world evidence study},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1097}
}
Kostenlos starten →